Cocrystal Discovery, Inc. signed a letter of intent to acquire Biozone Pharmaceuticals, Inc. (OTCBB:BZNE) from Opko Health, Inc. (NYSE:OPK), Frost Group, LLC and others in a reverse merger transaction on November 27, 2013. Under the terms of the merger agreement, current shareholders of Biozone Pharmaceuticals and Cocrystal Discovery will own 40% and 60% of the combined company, respectively. The combined company will initially continue to trade on the OTCBB under the symbol BZNE. The combined company will operate as Cocrystal Pharma, Inc. and will be based in Bothell, Washington.

Gary Wilcox, Chief Executive Officer and Chairman of Cocrystal Discovery will become the Chief Executive Officer and Chairman of the combined company. Roger Kornberg, Chief Scientist and a Director of Cocrystal Discovery, will keep the title of Chief Scientist of the combined company. The deal is subject to customary conditions. The merger is expected to close at the end of 2013.

As on January 2, 2014, Cocrystal Discovery signed a definitive agreement to acquire Biozone Pharmaceuticals. According to the terms of merger, each share of Cocrystal common stock shall be converted into 0.07454 shares of Biozone Series B. Elliot Maza, Roberto Prego-Novo and Brian Keller, directors of Biozone, resigned effective at the time of the closing of the merger. The Board of Biozone and the Board of Directors of Cocrystal have approved and declared advisable the merger. Michael D. Harris of Nason, Yeager, Gerson, White & Lioce, P.A. acted as a legal advisor to Biozone Pharmaceuticals.

Cocrystal Discovery, Inc. completed the acquisition of Biozone Pharmaceuticals, Inc. (OTCBB:BZNE) from Opko Health, Inc. (NYSE:OPK), Frost Group, LLC and others in a reverse merger transaction on January 2, 2014. Phillip Frost, Sam Lee, Steven Rubin and Jane Hsiao were appointed as Board of Directors of Cocrystal Discovery.